These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 12512697)
21. Synthesis of thieno[2,3-b]pyridinones acting as cytoprotectants and as inhibitors of [3H]glycine binding to the N-methyl-D-aspartate (NMDA) receptor. Buchstaller HP; Siebert CD; Steinmetz R; Frank I; Berger ML; Gottschlich R; Leibrock J; Krug M; Steinhilber D; Noe CR J Med Chem; 2006 Feb; 49(3):864-71. PubMed ID: 16451052 [TBL] [Abstract][Full Text] [Related]
22. Third generation thrombolytics for the treatment of ischemic stroke. Qureshi AI; Pande RU; Kim SH; Hanel RA; Kirmani JF; Yahia AM Curr Opin Investig Drugs; 2002 Dec; 3(12):1729-32. PubMed ID: 12528307 [TBL] [Abstract][Full Text] [Related]
23. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289 [TBL] [Abstract][Full Text] [Related]
24. [A component of earthworm fibrinolytic enzyme having higher thrombolytic activity than total components in vivo]. Zhao XY; Liu ZM; Jing TY; Wu JX; Zhao ZY Yao Xue Xue Bao; 2006 Nov; 41(11):1068-73. PubMed ID: 17262949 [TBL] [Abstract][Full Text] [Related]
25. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Pinto DJ; Orwat MJ; Koch S; Rossi KA; Alexander RS; Smallwood A; Wong PC; Rendina AR; Luettgen JM; Knabb RM; He K; Xin B; Wexler RR; Lam PY J Med Chem; 2007 Nov; 50(22):5339-56. PubMed ID: 17914785 [TBL] [Abstract][Full Text] [Related]
26. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E; Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526 [TBL] [Abstract][Full Text] [Related]
27. Comparison of safety and efficacy of the various thrombolytic agents. Ouriel K Rev Cardiovasc Med; 2002; 3 Suppl 2():S17-24. PubMed ID: 12556739 [TBL] [Abstract][Full Text] [Related]
29. Iliac venous stenting: antithrombotic efficacy of PD0348292, an oral direct Factor Xa inhibitor, compared with antiplatelet agents in pigs. McBane RD; Leadley RJ; Baxi SM; Karnicki K; Wysokinski W Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):413-8. PubMed ID: 18096830 [TBL] [Abstract][Full Text] [Related]
30. A new class of anti-thrombosis hexahydropyrazino-[1',2':1,6]pyrido-[3,4-b]-indole-1,4-dions: design, synthesis, logK determination, and QSAR analysis. Liu J; Wu G; Cui G; Wang WX; Zhao M; Wang C; Zhang Z; Peng S Bioorg Med Chem; 2007 Sep; 15(17):5672-93. PubMed ID: 17590343 [TBL] [Abstract][Full Text] [Related]
31. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial. Serebruany VL; Malinin AI; Pokov AN; Hanley DF Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263 [TBL] [Abstract][Full Text] [Related]
32. [Effect of Xuesaitong drop pills on experimerntal thrombosis and thrombolysis in rats]. Chen YH; Zhang SF; Sun JN; Wu JY; Jia ZH Zhongguo Zhong Yao Za Zhi; 2007 Feb; 32(3):253-6. PubMed ID: 17432152 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E; Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826 [TBL] [Abstract][Full Text] [Related]